{"url_path":"/sec/gtbp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-023346-index.html","accession_number":"0001493152-26-023346","cik":"0000109657","ticker":"GTBP","issuer_name":"GT Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-023346-index.html","primary_entity_key":"0000109657","primary_entity_name":"GT Biopharma, Inc."},"word_count":63,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\n**Rule\n10b5-1 Trading Plans**\n\n \n\nDuring\nthe three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act\nof 1934, as amended) adopted, amended, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading\narrangement,” as each term is defined in Item 408 of Regulation S-K.\n\n \n\n28"}